NeurAxis (NASDAQ:NRXS) & Orchestra BioMed (NASDAQ:OBIO) Financial Analysis

NeurAxis (NASDAQ:NRXS) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk and earnings.

Earnings and Valuation

This table compares NeurAxis and Orchestra BioMed”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeurAxis	$5.32 million	18.54	-$14.63 million	($0.78)	-10.06
Orchestra BioMed	$33.48 million	10.44	-$52.70 million	($0.85)	-6.84

NeurAxis has higher earnings, but lower revenue than Orchestra BioMed. NeurAxis is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

NeurAxis has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500. Comparatively, Orchestra BioMed has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500.

Insider and Institutional Ownership

11.8% of NeurAxis shares are held by institutional investors. Comparatively, 53.2% of Orchestra BioMed shares are held by institutional investors. 21.1% of NeurAxis shares are held by insiders. Comparatively, 7.5% of Orchestra BioMed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and price targets for NeurAxis and Orchestra BioMed, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeurAxis	0	1	1	0	2.50
Orchestra BioMed	1	0	6	0	2.71

NeurAxis presently has a consensus target price of $13.00, suggesting a potential upside of 65.61%. Orchestra BioMed has a consensus target price of $13.17, suggesting a potential upside of 126.43%. Given Orchestra BioMed’s stronger consensus rating and higher probable upside, analysts clearly believe Orchestra BioMed is more favorable than NeurAxis.

Profitability

This table compares NeurAxis and Orchestra BioMed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NeurAxis	-492.76%	N/A	-641.25%
Orchestra BioMed	-184.60%	-149.61%	-54.15%

About NeurAxis

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.

About Orchestra BioMed

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.